Clinical Trial Update: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the combination of acalabrutinib, venetoclax, and rituximab in treatment-naïve mantle cell lymphoma; the study is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)
• Venclexa (venetoclax)

Snippet

Sponsor: AstraZeneca | Conditions: Mantle Cell Lymphoma (MCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING